


10/038,113

=>  
Uploading C:\Program Files\Stnexp\Queries\1132.str

L6           STRUCTURE UPLOADED

=> d l6  
L6 HAS NO ANSWERS  
L6           STR



*included species*

Structure attributes must be viewed using STN Express query preparation.

=> s l6 sss sam  
SAMPLE SEARCH INITIATED 15:10:21 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 4695 TO ITERATE

21.3% PROCESSED      1000 ITERATIONS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

50 ANSWERS

FULL FILE PROJECTIONS:   ONLINE   \*\*COMPLETE\*\*  
                          BATCH    \*\*COMPLETE\*\*  
PROJECTED ITERATIONS:       89792 TO   98008  
PROJECTED ANSWERS:           73278 TO   80718

L7           50 SEA SSS SAM L6

=> s l6 sss full  
FULL SEARCH INITIATED 15:10:28 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 93401 TO ITERATE

100.0% PROCESSED    93401 ITERATIONS  
SEARCH TIME: 00.00.01

76640 ANSWERS



L8           76640 SEA SSS FUL L6

=> file hcaplus

10/038,113

=> d 110 abs ibib kwic hitstr 60, 68, 74

L10 ANSWER 60 OF 98 HCAPLUS COPYRIGHT 2004 ACS on STN  
GI



AB Title compds. I [E = bond, (substituted) amino, (alkyl)thio, (alkyl)sulfinyl, (alkyl)sulfonyl, CH(OH), O, CO, K = O, S, NH, (substituted)alkylamino, etc.; X = bond, CO, O, S, NH, etc.; R1 = HO2C, HO3S, C1-4 polyfluoroalkylsulfonylamino, H2NSO2, (HO)2P(O), (substituted)heterocyclyl, etc.; R2a, R2b = H, halo, H2N, O2N, C1-4 alkyl, C1-4 alkoxy, etc.; R3a = H, halo, C1-6 alkyl, C1-6 alkoxy, etc.; R3b = H, halo, O2N, C1-6 alkyl, hydroxy-C1-4-alkyl, etc.; R6 = C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl which can be substituted, R8 = H, HO, (alkyl)(dialkyl)amino, etc.; r = 1, 2] and their salts, as angiotensin II antagonists useful in treatment of hypertension, **ocular** hypertension, on certain CNS disorders (no data) are prepared  
5-Amino-3-butyl-1-(2-chlorophenyl)-4-[(2-tetrazol-5-ylbiphenyl-4-yl)methyl]pyrazole (preparation given) in CCl4 was diazotized to give the pyrazole derivative which was heated with NaCN in DMSO to give the nitrilepyrazole which was diluted with brine and extracted with ether to give the title pyrazole II. Pharmaceutical formulations comprising II are given.

ACCESSION NUMBER:	1992:106284 HCAPLUS
DOCUMENT NUMBER:	116:106284
TITLE:	Preparation of substituted pyrazoles, isoxazoles and isothiazoles as angiotensin II antagonists
INVENTOR(S):	Allen, Eric E.; Greenlee, William J.; MacCoss, Malcolm; Ashton, Wallace T.
PATENT ASSIGNEE(S):	Merck and Co., Inc., USA
SOURCE:	PCT Int. Appl., 171 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

DELACROIX

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9115479	A1	19911017	WO 1991-US1952	19910327 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2079343	AA	19911001	CA 1991-2079343	19910327 <--
EP 523141	A1	19930120	EP 1991-907490	19910327 <--
R: CH, DE, FR, GB, IT, LI, NL				
JP 05505822	T2	19930826	JP 1991-507326	19910327 <--
PRIORITY APPLN. INFO.:			US 1990-501469	19900330
			WO 1991-US1952	19910327
OTHER SOURCE(S): MARPAT 116:106284				
PI WO 9115479 A1	<b>19911017</b>			
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9115479	A1	19911017	WO 1991-US1952	19910327 <--
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2079343	AA	19911001	CA 1991-2079343	19910327 <--
EP 523141	A1	19930120	EP 1991-907490	19910327 <--
R: CH, DE, FR, GB, IT, LI, NL				
JP 05505822	T2	19930826	JP 1991-507326	19910327 <--
AB . . . H, HO, (alkyl)(dialkyl)amino, etc.; r = 1, 2] and their salts, as				
angiotensin II antagonists useful in treatment of hypertension,				
ocular hypertension, on certain CNS disorders (no data) are prepared				
5-Amino-3-butyl-1-(2-chlorophenyl)-4-[(2-tetrazol-5-ylbiphenyl-4-				
yl)methyl]pyrazole (preparation given) in CCl <sub>4</sub> was diazotized to give the				
pyrazole. . .				
IT <b>Glaucoma</b> (disease)				
(treatment of, substituted pyrazoles, isothiazoles, and isoxazoles for)				
IT 937-12-2P	1118-03-2P	70102-84-0P	70680-21-6P	114772-39-3P
114772-53-1P	120568-11-8P	124750-51-2P	124750-53-4P	138444-15-2P
<b>138733-39-8P</b>	138733-40-1P	138733-41-2P	138733-42-3P	
138733-43-4P	138733-44-5P	138733-45-6P	138733-46-7P	138733-47-8P
138733-48-9P	138733-49-0P	138733-50-3P	138733-51-4P	138733-52-5P
138733-53-6P	138733-54-7P	138733-55-8P	138733-56-9P	138733-57-0P
138733-58-1P	138733-59-2P	138733-60-5P	138733-61-6P	138762-16-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT				
(Reactant or reagent)				
(preparation and reaction of, in preparation of angiotensin II inhibitors)				
IT 137645-69-3P	138531-94-9P	<b>138717-60-9P</b>	138717-61-0P	
138717-62-1P	138717-63-2P	138717-64-3P	138717-65-4P	138717-66-5P
138717-67-6P	138717-68-7P	138717-69-8P	138717-70-1P	138717-71-2P
138717-72-3P	138717-73-4P	138717-74-5P	138717-75-6P	138717-76-7P
138717-77-8P	<b>138717-78-9P</b>	<b>138717-79-0P</b>		
<b>138717-80-3P</b>	<b>138717-81-4P</b>	<b>138717-82-5P</b>		
<b>138717-83-6P</b>	<b>138717-84-7P</b>	<b>138717-85-8P</b>		
<b>138717-86-9P</b>	<b>138717-87-0P</b>	<b>138717-88-1P</b>		
<b>138717-89-2P</b>	<b>138717-90-5P</b>	<b>138717-91-6P</b>		
<b>138717-92-7P</b>	<b>138717-93-8P</b>	<b>138717-94-9P</b>		
<b>138717-95-0P</b>	<b>138717-96-1P</b>	<b>138717-97-2P</b>		
<b>138717-98-3P</b>	<b>138717-99-4P</b>	<b>138718-00-0P</b>		
<b>138718-01-1P</b>	<b>138718-02-2P</b>	<b>138718-03-3P</b>		
138718-04-4P	138718-05-5P	138732-48-6P	138732-49-7P	138732-50-0P
138732-51-1P	138732-52-2P	138732-53-3P	138732-54-4P	138732-55-5P
138732-56-6P	138732-57-7P	138732-58-8P	138732-59-9P	138732-60-2P
138732-61-3P	138732-62-4P	138732-63-5P	138732-64-6P	138732-65-7P
138732-66-8P	138732-67-9P	138732-68-0P	138732-69-1P	138732-70-4P

138732-71-5P	138732-72-6P	138732-73-7P	138732-74-8P	138732-75-9P
138732-76-0P	138732-77-1P	138732-78-2P	138732-79-3P	138732-80-6P
138732-81-7P	138732-82-8P	138732-83-9P	138732-84-0P	138732-85-1P
138732-86-2P	138732-87-3P	138732-88-4P	138732-89-5P	138732-90-8P
138732-91-9P	138732-92-0P	138732-93-1P	138732-94-2P	138732-95-3P
138732-96-4P	138732-97-5P	138732-98-6P	138732-99-7P	138733-00-3P
138733-01-4P	138733-02-5P	138733-03-6P	138733-04-7P	138733-05-8P
138733-06-9P	138733-07-0P	138733-08-1P	138733-09-2P	138733-10-5P
138733-11-6P	138733-12-7P	138733-13-8P	138733-14-9P	138733-15-0P
138733-16-1P	138733-17-2P	138733-18-3P	138733-19-4P	138733-20-7P
138733-21-8P	138733-22-9P	138733-23-0P	138733-24-1P	138733-25-2P
138733-26-3P	138733-27-4P	138733-28-5P	138733-29-6P	138733-30-9P
138733-31-0P	138733-32-1P	138733-33-2P	138733-34-3P	138733-35-4P
138733-36-5P	138733-37-6P	138733-38-7P	138762-09-1P	138762-10-4P
138762-11-5P	138762-12-6P	138762-13-7P	138762-14-8P	138762-15-9P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as angiotensin II inhibitor)


IT **138733-39-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of angiotensin II inhibitors)

RN 138733-39-8 HCAPLUS

CN 5-Isioxazolamine, 3-butyl-4-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



IT 138717-60-9P 138717-78-9P 138717-79-0P  
 138717-80-3P 138717-81-4P 138717-82-5P  
 138717-83-6P 138717-84-7P 138717-85-8P  
 138717-86-9P 138717-87-0P 138717-88-1P  
 138717-89-2P 138717-90-5P 138717-91-6P  
 138717-92-7P 138717-93-8P 138717-94-9P  
 138717-95-0P 138717-96-1P 138717-97-2P  
 138717-98-3P 138717-99-4P 138718-00-0P  
 138718-01-1P 138718-02-2P 138718-03-3P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as angiotensin II inhibitor)

RN 138717-60-9 HCAPLUS


CN 5-Isioxazolamine, 3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

10/038,113




RN 138717-78-9 HCAPLUS

CN 5-Isoxazolecarboxylic acid, 3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138717-79-0 HCAPLUS

CN 5-Isoxazolecarboxylic acid, 4-[[2'-[(benzoylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]-3-butyl- (9CI) (CA INDEX NAME)




RN 138717-80-3 HCAPLUS

CN 5-Isoxazolecarboxylic acid, 3-butyl-4-[[2'-[[[(trifluoroacetyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)


DELACROIX

10/038,113




RN 138717-81-4 HCAPLUS

CN 5-Isoxazolecarboxylic acid, 3-butyl-4-[[2'-[[[(trifluoromethyl)sulfonyl]amino][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138717-82-5 HCAPLUS

CN 5-Isoxazolecarboxylic acid, 3-butyl-4-[[2'-[[[(cyclopropylcarbonyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)




DELACROIX

10/038,113


RN 138717-83-6 HCAPLUS

CN 5-Isoxazolecarboxylic acid, 4-[[2'-[[[(diphenylacetyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 138717-84-7 HCAPLUS

CN 5-Isoxazolecarboxylic acid, 3-propyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138717-85-8 HCAPLUS

CN 5-Isoxazolecarboxylic acid, 4-[[2'-[[[(cyclopropylcarbonyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-3-propyl- (9CI) (CA INDEX NAME)




DELACROIX

10/038,113


RN 138717-86-9 HCAPLUS

CN 5-Isoxazolecarboxylic acid, 3-propyl-4-[[2'-[[[(trifluoromethyl)sulfonyl]amino][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 138717-87-0 HCAPLUS

CN 5-Isioxazolecarboxamide, 3-butyl-N-(phenylsulfonyl)-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138717-88-1 HCAPLUS

CN Methanesulfonamide, N-[3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 138717-89-2 HCAPLUS

CN Ethanesulfonamide, N-[3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]-1,1,2,2,2-pentafluoro- (9CI) (CA INDEX NAME)

DELACROIX




10/038,113




RN 138717-90-5 HCAPLUS

CN Benzamide, N-[[4'-[[3-butyl-5-[[trifluoromethyl]sulfonyl]amino]-4-isoxazolyl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 138717-91-6 HCAPLUS

CN 5-Isioxazolecarboxylic acid, 4-[[2'-{(benzoylamino)sulfonyl][1,1'-biphenyl]-4-yl]methyl]-3-propyl- (9CI) (CA INDEX NAME)




RN 138717-92-7 HCAPLUS

DELACROIX


10/038,113

CN Cyclopropanecarboxamide, N-[[4'-[[3-butyl-5-[[trifluoromethyl)sulfonyl]amino]-4-isoxazolyl)methyl][1,1'-biphenyl]-2-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 138717-93-8 HCAPLUS


CN Methanesulfonamide, N-[3-butyl-4-[[2'-[[trifluoromethyl)sulfonyl]amino][1,1'-biphenyl]-4-yl)methyl]-5-isoxazolyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 138717-94-9 HCAPLUS


CN Methanesulfonamide, 1,1,1-trifluoro-N-[3-propyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl]-5-isoxazolyl]- (9CI) (CA INDEX NAME)

10/038,113




RN 138717-95-0 HCAPLUS

CN Ethanesulfonamide, 1,1,2,2,2-pentafluoro-N-[3-propyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]- (9CI) (CA INDEX NAME)



RN 138717-96-1 HCAPLUS

CN Benzamide, N-[[4'-[[3-propyl-5-[[[(trifluoromethyl)sulfonyl]amino]-4-isoxazolyl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 138717-97-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[[4'-[[3-propyl-5-[[[(trifluoromethyl)sulfonyl]amino]-4-isoxazolyl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)

DELACROIX


10/038,113

SOURCE: U.S., 4 pp. Cont. of U.S. Ser. No. 18,330, abandoned.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
	US 4888327	A	19891219	US 1988-228621	19880804 <--
PRIORITY APPLN. INFO.:				US 1984-659352	19841010
				US 1987-18330	19870224
PI	US 4888327 A	19891219			
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 4888327	A	19891219	US 1988-228621	19880804 <--
AB	Antibiotic synergistic compns. for topical administration contain an aminoglycoside, a benzylpyrimidine, and a sulfonamide. An <b>ophthalmic</b> ointment was prepared consisting of tobramycin 3, trimethoprim 3, sulfonamide 60, mineral oil 150, petrolatum base 200, and chlorobutanol 5. . .				
ST	antibiotic ointment <b>ophthalmic</b>				
IT	Sulfonamides				
	RL: BIOL (Biological study)				
	( <b>ophthalmic</b> formulations containing aminoglycoside antibiotics and benzylpyrimidines and)				
IT	Antibiotics				
	(aminoglycoside, <b>ophthalmic</b> formulations containing sulfonamides and benzylpyrimidines and)				
IT	Sulfonamides				
	RL: BIOL (Biological study)				
	(mixts., with tobramycin and trimethoprim, antibiotic synergistic <b>ophthalmic</b> formulations containing)				
IT	Pharmaceutical dosage forms				
	(solns., <b>ophthalmic</b> , aminoglycoside-benzylpyrimidine-sulfonamide mixts. in)				
IT	<b>127-69-5D</b> , mixture with benzylpyrimidine derivative and tobramycin				
	738-70-5D, mixts. with sulfonamides and tobramycin 32986-56-4D, mixts. with benzylpyrimidine derivs. and sulfonamides <b>126855-15-0</b>				
	RL: BIOL (Biological study)				
	(antibiotic synergistic <b>ophthalmic</b> formulation containing)				
IT	106564-15-2D, derivs., mixts. with aminoglycoside antibiotics and sulfonamides				
	RL: BIOL (Biological study)				
	( <b>ophthalmic</b> formulations containing)				
IT	<b>127-69-5D</b> , mixture with benzylpyrimidine derivative and tobramycin				
	<b>126855-15-0</b>				
	RL: BIOL (Biological study)				
	(antibiotic synergistic <b>ophthalmic</b> formulation containing)				
RN	127-69-5 HCAPLUS				
CN	Benzenesulfonamide, 4-amino-N-(3,4-dimethyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)				

DELACROIX

10/038,113



RN 126855-15-0 HCAPLUS


CN D-Streptamine, O-3-amino-3-deoxy- $\alpha$ -D-glucopyranosyl-(1 $\rightarrow$ 6)-O-[2,6-diamino-2,3,6-trideoxy- $\alpha$ -D-ribo-hexopyranosyl-(1 $\rightarrow$ 4)]-2-deoxy-, mixt. with 4-amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamide and 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine (9CI) (CA INDEX NAME)

CM 1

CRN 32986-56-4

CMF C18 H37 N5 O9


Absolute stereochemistry.



CM 2

CRN 738-70-5

CMF C14 H18 N4 O3




DELACROIX

10/038,113

CM 3

CRN 723-46-6

CMF C10 H11 N3 O3 S



L10 ANSWER 74 OF 98 HCAPLUS COPYRIGHT 2004 ACS on STN

AB A buffered solution for the local treatment of eye infections contains neoxazol 4, diethanolamine 1.5-1.7, dextran 40,000 1-2, chlorhexidine acetate or diacetate 0.001-0.01, EDTA-Na2 0.05-0.1, NaCl 0.7-0.9, methylene blue 0.0025-0.005 and water to 100%.

ACCESSION NUMBER: 1988:62494 HCAPLUS

DOCUMENT NUMBER: 108:62494

TITLE: Neoxazol-containing **ophthalmic** solution

INVENTOR(S): Ban, Petra; Chereches, Silvia; Olteanu, Mircea; Banacu, Ioan

PATENT ASSIGNEE(S): Intreprinderea de Medicamente "Biofarm", Rom.

SOURCE: Rom., 2 pp.

CODEN: RUXXA3

DOCUMENT TYPE: Patent

LANGUAGE: Romanian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 91196	B1	19870330	RO 1985-117579	19850208 <--
PRIORITY APPLN. INFO.:			RO 1985-117579	19850208

TI Neoxazol-containing **ophthalmic** solution

PI RO 91196 B1 **19870330**

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 91196	B1	19870330	RO 1985-117579	19850208 <--

IT **127-69-5**, Neoxazol

RL: BIOL (Biological study)  
(**ophthalmic** solution containing)


IT **127-69-5**, Neoxazol

RL: BIOL (Biological study)  
(**ophthalmic** solution containing)

RN **127-69-5** HCAPLUS

CN Benzenesulfonamide, 4-amino-N-(3,4-dimethyl-5-isoxazolyl)- (9CI) (CA INDEX NAME)

10/038,113



10/038,113

```
=> s l8 and (glaucom? or ocular? or intra(2a)intraocular? or ophthal?)
    28367 L8
    5488 GLAUCOM?
    13724 OCULAR?
    43439 INTRA
    7174 INTRAOCULAR?
    4 INTRA(2A) INTRAOCULAR?
    11359 OPHTHAL?
L9      208 L8 AND (GLAUCOM? OR OCULAR? OR INTRA(2A) INTRAOCULAR? OR OPHTHAL
        ?)

=> s l9 and py<=2000
    20616029 PY<=2000
L10     98 L9 AND PY<=2000

=> d l10 ibib 1-98
```



10/038,113

=> d his

(FILE 'HOME' ENTERED AT 15:06:56 ON 23 JUN 2004)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 23 JUN 2004

L1 STRUCTURE UPLOADED  
L2 0 S L1 SSS SAM  
L3 8 S L1 SSS FULL

FILE 'HCAPLUS, USPATFULL, MEDLINE, BIOSIS, EMBASE, SCISEARCH' ENTERED AT  
15:08:15 ON 23 JUN 2004

FILE 'HCAPLUS, USPATFULL' ENTERED AT 15:08:42 ON 23 JUN 2004

L4 6 S L3  
L5 6 DUP REM L4 (0 DUPLICATES REMOVED)

FILE 'STNGUIDE' ENTERED AT 15:09:21 ON 23 JUN 2004

FILE 'REGISTRY' ENTERED AT 15:10:01 ON 23 JUN 2004

L6 STRUCTURE UPLOADED  
L7 50 S L6 SSS SAM  
L8 76640 S L6 SSS FULL

FILE 'HCAPLUS' ENTERED AT 15:10:37 ON 23 JUN 2004


L9 208 S L8 AND (GLAUCOM? OR OCULAR? OR INTRA(2A) INTRAOCULAR? OR OPHT  
L10 98 S L9 AND PY<=2000

FILE 'STNGUIDE' ENTERED AT 15:12:14 ON 23 JUN 2004

FILE 'HCAPLUS' ENTERED AT 15:14:30 ON 23 JUN 2004


FILE 'STNGUIDE' ENTERED AT 15:15:23 ON 23 JUN 2004

10/038,113



RN 138717-98-3 HCAPLUS


CN 1H-Tetrazole, 5-[4'-[[[3-butyl-5-[[[4-chlorophenyl)methyl]sulfinyl]-4-isoxazolyl]methyl][1,1'-biphenyl]-2-yl]- (9CI) (CA INDEX NAME)



RN 138717-99-4 HCAPLUS


CN Benzoic acid, 2-[[[3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]thio]methyl]- (9CI) (CA INDEX NAME)

10/038,113




RN 138718-00-0 HCAPLUS

CN 5-Isoxazolecarboxamide, 3-butyl-N-[(1-methylethyl)sulfonyl]-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 138718-01-1 HCAPLUS

CN 5-Isoxazolecarboxamide, 3-butyl-N-(cyclopropylsulfonyl)-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)




RN 138718-02-2 HCAPLUS

CN Benzenesulfonamide, N-[3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]-4-fluoro- (9CI) (CA INDEX NAME)


DELACROIX

10/038,113



RN 138718-03-3 HCAPLUS

CN 3-Pyridinesulfonamide, N-[3-butyl-4-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-5-isoxazolyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 68 OF 98 HCAPLUS COPYRIGHT 2004 ACS on STN

AB Antibiotic synergistic compns. for topical administration contain an aminoglycoside, a benzylpyrimidine, and a sulfonamide. An **ophthalmic** ointment was prepared consisting of tobramycin 3, trimethoprim 3, sulfonamide 60, mineral oil 150, petrolatum base 200, and chlorobutanol 5 mg/g.

ACCESSION NUMBER: 1990:204729 HCAPLUS

DOCUMENT NUMBER: 112:204729

TITLE: Topical antibiotic compositions

INVENTOR(S): Edwards, John G.

PATENT ASSIGNEE(S): Alcon Laboratories, Inc., USA

DELACROIX